南非将于2026年3月开始推出为期六个月的艾滋病毒预防药物,由一笔2 900万美元的赠款支助,用于456 000名高危人群。 South Africa will begin rolling out a six-month HIV prevention drug in March 2026, supported by a $29 million grant for 456,000 high-risk people.

南非计划从2026年3月开始推出Lenacapavir, 这是一种长效艾滋病毒预防药物,每剂量提供6个月的防护。 South Africa plans to roll out Lenacapavir, a long-acting HIV prevention drug offering six months of protection per dose, starting in March 2026. 2 900万美元的全球基金赠款将在两年内支助456 000人,以少女、孕妇和关键人口等高风险群体为对象。 The $29 million Global Fund grant will support 456,000 people over two years, targeting high-risk groups like adolescent girls, pregnant women, and key populations. 该药物通过非专利药物和伙伴关系生产,价格低廉,在试验中显示出很高的功效,由卫生组织推荐。 The drug, produced affordably through generics and partnerships, shows high efficacy in trials and is recommended by the WHO. 推广工作将侧重于23个高事故区,利用360个诊所,并正在努力确保当地制造业的安全,并将该药物纳入国家融资。 The rollout will focus on 23 high-incident districts using 360 clinics, with efforts underway to secure local manufacturing and integrate the drug into national financing.